Home About us Editorial board Ahead of print Browse Articles Search Submit article Instructions Subscribe Contacts Login 
  • Users Online: 622
  • Home
  • Print this page
  • Email this page
Year : 2022  |  Volume : 27  |  Issue : 1  |  Page : 87

Serum selenium status in Graves' disease and Hashimoto's thyroiditis in an iodine-sufficient area: A case–control study

1 Department of Endocrinology and Metabolism, Zahedan University of Medical Sciences, Zahedan, Iran
2 Department of Pediatric Nephrology, Zahedan University of Medical Sciences, Zahedan, Iran

Correspondence Address:
Dr. Zahra Heidari
Integrating the Campus of the University of Medical Sciences Doctor Hesabi Square, P.O.BOX: 98167-43175, Sistan and Baluchestan Province, Zahedan
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/jrms.jrms_57_21

Rights and Permissions

Background: Selenium (Se) can be found in the molecular structure of selenoproteins; including thioredoxin reductase and glutathione peroxidase and also in Type I and II deiodinases. Previous studies have shown that Se deficiency has been linked to autoimmune thyroid disease (AITD). In the present study, we investigated the serum Se levels of patients with Graves' disease (GD), Hashimoto's thyroiditis (HT), and euthyroid individuals as a control group. Materials and Methods: The present study was performed on patients with newly diagnosed AITD (GD and HT). The control group was matched with the case group in terms of parameters such as age and sex. Free thyroxine, free triiodothyronine, thyroid-stimulating hormone, antithyroid peroxidase, antithyroglobulin, and serum Se levels were measured in all participants. These parameters were compared between groups. Results: Data from 132 patients with HT, 120 patients with GD, and 120 healthy euthyroid patients as a control group were analyzed. The Se level in patients with HT (104.36 μg/l) and GD (97.68 μg/l) was significantly lower than in the control group (122.63 μg/l) (P < 0.001). The incidence of Se deficiency in patients with HT, GD, and in the control group was 15.2%, 2.5%, and 2.5%, respectively (P < 0.001). In patients with GD, 34 patients (28.33%) had Graves' orbitopathy. Se levels in patients with orbitopathy were significantly lower than in patients without orbitopathy. Conclusion: The serum Se level was significantly lower in newly diagnosed patients with GD and HT than in the control group. Overall, Se deficiency can be considered a risk factor for AITDs.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded45    
    Comments [Add]    

Recommend this journal